CN103566198A - Application of gastrodia elata and gastrodin in preparation of product used for treating non-alcoholic fatty liver disease - Google Patents
Application of gastrodia elata and gastrodin in preparation of product used for treating non-alcoholic fatty liver disease Download PDFInfo
- Publication number
- CN103566198A CN103566198A CN201210276077.2A CN201210276077A CN103566198A CN 103566198 A CN103566198 A CN 103566198A CN 201210276077 A CN201210276077 A CN 201210276077A CN 103566198 A CN103566198 A CN 103566198A
- Authority
- CN
- China
- Prior art keywords
- gram
- gastrodine
- order
- rhizoma gastrodiae
- fiber crops
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention relates to a new application of gastrodia elata and gastrodin in preparation of a product used for treating a non-alcoholic fatty liver disease and a unique molecular mechanism of the gastrodia elata and gastrodin. Scientific experiments show that gastrodia elata/gastrodin has an obvious treatment and improvement effect on the non-alcoholic fatty liver disease by virtue of up-regulation of a peroxisome fatty acid beta oxidation key enzyme, namely acyl-CoA oxidases 3 (ACOX3), and can become a brand new clinical medicine used for treating the non-alcoholic fatty liver disease.
Description
Technical field:
The present invention relates to new purposes and unique molecule mechanism thereof of Rhizoma Gastrodiae/Therapeutic Efficacy of Gastrodin non-alcoholic fatty liver disease.
Background technology:
In hepatocyte except non-alcoholic fatty liver disease refers to due to ethanol and other clear and definite damage liver factors, fat is excessively accumulated the pathology syndrome for principal character, and main cause is relevant with fat and glucose metabolism disorder etc.Main pathology physiological performance is liver fat degeneration, inflammatory cell infiltration, abnormal liver function etc.Along with development and the living standards of the people raising of Chinese national economy, the incidence rate of non-alcoholic fatty liver disease constantly increases.Fatty liver, as controlled not in time, can cause even hepatocarcinoma of liver cirrhosis.At present, the treatment of non-alcoholic fatty liver disease, except living habit change, motion, dietary structure change, there is no Drug therapy targetedly.The present invention finds by scientific experiments, and Rhizoma Gastrodiae/gastrodine obviously improves non-alcoholic fatty liver disease by unique molecule mechanism, and has no side effect.The effect that this is new, there is not yet relevant report both domestic and external up to now.
Rhizoma Gastrodiae original name rhizoma gastrodiae ， China has the clinical practice of more than 2000 year historical, and the main effective ingredient of Rhizoma Gastrodiae is gastrodine (4-methylol benzene-β-D pyranglucoside).Rhizoma Gastrodiae/gastrodine is mainly used in treating nervous system disease at present clinically, as vertebra one basilar artery insufficiency, headache, dizzy etc., is not still developed to the successful product for the treatment of non-alcoholic fatty liver disease.
The object of this invention is to provide Chinese traditional herbs Rhizoma Gastrodiae/gastrodine in new purposes and the unique molecular mechanism thereof of the invention for the treatment of non-alcoholic fatty liver disease.
Summary of the invention:
The present invention relates to: Rhizoma Gastrodiae and the gastrodine purposes in the product of preparation treatment non-alcoholic fatty liver disease.
The present invention relates to: the purposes of the gastrodine in Rhizoma Gastrodiae in preparation treatment non-alcoholic fatty liver disease product.
The product the present invention relates to includes, without being limited to: medicine, food, health product.
The present invention relates to: comprise and do not limit, Rhizoma Gastrodiae or gastrodine raise the purposes of the medicine of hepatocyte ACOD 3 mRNA of (ACOX3) and the expression of albumen in preparation.
The present invention relates to: Rhizoma Gastrodiae or gastrodine are made peroral dosage form.
The present invention relates to: Rhizoma Gastrodiae adopts micropowder, and its granularity is 200-1000 order.
The present invention relates to: Rhizoma Gastrodiae adopts rice fiber crops, the numb composition of arrow of following ratio: the ratio between rice fiber crops and arrow fiber crops is: 1-10: 20-300; Wherein the granularity of rice fiber crops is that the granularity of 200-1000 order, arrow fiber crops is 80-600 order.
The present invention relates to: the dosage of Rhizoma Gastrodiae is 200-1000 milligram.
The present invention relates to: the dosage of gastrodine is 5-10 milligram.
The present invention relates to tablet, this tablet composed as follows:
800 20-40 gram of order rice fiber crops, 200 order arrow fiber crops 220-500 gram; Or gastrodine 3-10 gram
200 order recrystallization lactose 40-120 gram, and, 600 order spray-dried lactose 50-140 gram; With
Pregelatinized Starch 10-40 gram; With
Magnesium stearate 2-10 gram; With
Sodium ascorbate 2-6 gram.
The present invention relates to tablet, this tablet preferably composed as follows:
220,320,420,500 grams of 800 20,25,30,40 grams of order rice fiber crops, 200 order arrow fiber crops; Or 3,6,8,10 grams of gastrodine
200 40,60,80,120 grams of order recrystallization lactose, and, 600 50,60,80,100,120,140 grams of order spray-dried lactoses; With
10,20,30,40 grams of pregelatinized Starch; With
2,6,8,10 grams of magnesium stearate; With
2,4,6 grams of sodium ascorbates.
The present invention relates to tablet, this tablet preferably composed as follows:
220,320,420,500 grams of 800 20,25,30,40 grams of order rice fiber crops, 200 order arrow fiber crops; Or 3,6,8,10 grams of gastrodine
200 40,60,80,120 grams of order recrystallization lactose, and, 600 50,60,80,100,120,140 grams of order spray-dried lactoses; With
20,30,40 grams of microcrystalline Cellulose;
10,20,30,40 grams of pregelatinized Starch; With
40,60,80 grams of crospolyvinylpyrrolidone; With
2,4,6,8,10 grams of magnesium stearate; With
2,4,6,8,10 grams of micropowder silica gels
Figure of description
Fig. 1 rat liver oil red dyeing normal control
The high fat contrast of dyeing of Fig. 2 rat liver oil red
Fig. 3 rat liver oil red coloration result gastrodine 10mg/kg
Fig. 4: after gastrodine processing HepG2 cell, energy dose dependent raises the mrna expression level of ACOX3
Fig. 5: after gastrodine processing HepG2 cell, energy dose dependent raises the protein expression level of ACOX3
The specific embodiment
The screening of Rhizoma Gastrodiae slice prescription
The screening of gastrodini prescription
The present invention adopts respectively lipomul gavage and high-fat and high-cholesterol diet to throw something and feed to induce Making Rat Models of Nonalcoholic, with gastrodine, Rhizoma Gastrodiae micropowder and tablet thereof, be used for treating animal, with lipitor or the positive contrast medicine of simvastatin, observe gastrodine, Rhizoma Gastrodiae micropowder and the improvement effect of tablet to fatty liver thereof.
In experiment, study the molecule mechanism that gastrodine improves fatty liver in vitro in addition.Specific experiment thes contents are as follows:
Gastrodine and tablet thereof the preventive effect to lipomul induction rat nonalcoholic fatty liver
1, material:
Laboratory animal: 40 of male SD rats, body weight 140-160g, numbers purchased from Beijing Vital River Experimental Animals Technology Co., Ltd.'s licence: SCXX (capital) 2007-0001.Feeding environment, Inst. of Medicinal Biological Technology, Chinese Academy of Medical Sciences's experimental animal room (SPF level), licence is numbered: SYXK (capital) 2007-0013.
Lipomul configuration: self-control lipomul formula is containing Adeps Sus domestica 30%, cholesterol 10%, tween 80 10%, propylene glycol 20%, cholate 3%, water 27%.Adeps Sus domestica, cholesterol and Tween 80 heating and melting are mixed and made into oil phase, and cholate is dissolved in after water, mixes and makes water with propylene glycol.After suitably cooling, oil phase and water are mixed to abundant stirring and evenly mixing and make lipomul.Medicine: gastrodine, white powder, Zhejiang Cheng Yi Pharmaceutical Co., Ltd produces, lot number: 20091005.
Gastrodine tablet, the tablet of gastrodini prescription 5
Positive drug: atorvastatin (lipitor, LIPITOR) lot number; The 196509K. date of manufacture 2009.11, effect duration 2012.10, pfizer inc.
Test kit: T-CHOL (TC), triglyceride (TG), low-density lipoprotein cholesterol (LDL-c), HDL-C (HDL-c) and GPT, GOT test kit are bought raw biological engineering high-tech company in Beijing.
Key instrument: full-automatic biochemical analyzing and testing instrument (HITACHI 7060 Automatic Analyzer), desk centrifuge etc.
2, method
Rat adaptability starts experiment after raising 2d.Experiment is divided into 5 groups, 6 of Normal groups, 10 of high fat (model) matched groups, all the other every group 8 animals, i.e. gastrodine 10mg/kg group, gastrodine tablet 50mg/kg group, lipitor 2.5mg/kg group at random.12h weighs on an empty stomach, the blood sampling of eye socket rear vein beard, the basic value of detection serum TC, TG, LDL-C.
By 4 groups of above-mentioned experiments, give common normal feedstuff.Model control group, gastrodine, gastrodine tablet and lipitor group give high fat breast (dosage 20ml/kg).Gavage gives gastrodine 10mg/kg, gastrodine tablet and LPT 2.5mg/kg after half an hour, gavage capacity is 10ml/kg.Give continuously 4 weeks.Animal ad lib and drinking-water, weigh weekly 2 times, in administration the 2nd week, 12h socket of the eye venous plexus blood sampling on an empty stomach in the 4th week, measures serum TC, TG, LDL-C, GOT, GPT index.The kit measurement that adopts Beijing Zhongsheng Biological Engineering High Technology Company to provide.
Pathologic finding: administration is after 4 weeks, puts to death animal, gets respectively to organize liver and fix with 10% formalin, repaiies respectively piece, through gradient alcohol dehydration, and paraffin embedding, section (thickness 5 μ M) HE dyes, om observation.Separately get liver liquid nitrogen freezing, liver fat granule is observed in oil red dyeing.
Statistical analysis: variance analysis is in conjunction with t check between group.
3, result
Pathological examination:
1) Normal group: 5 examples (5/5) hepatic tissue has no hepatic cell fattydegeneration, hepatic necrosis, liver proliferation of fibrous tissue and cell infiltration.
2) high fat group: 7 examples (7/7) hepatic cell fattydegeneration, 3 examples are slight pathological changes, and 3 examples are moderate pathological changes, and 1 example is severe pathological changes.5 examples (5/7) special mess hepatic necrosis companion cell infiltration, wherein 4 examples are slight pathological changes, 1 example is moderate pathological changes.
3) gastrodine 10mg/kg group: 7 examples (7/7) hepatic cell fattydegeneration, is slight pathological changes.The little focal necrosis companion of 5 examples (5/7) cell infiltration, is slight pathological changes.
4) gastrodine tablet 50mg/kg group: 4 examples (5/7) hepatic cell fattydegeneration, is slight pathological changes.The little focal necrosis companion of 3 examples (3/7) cell infiltration, is slight pathological changes.
Conclusion:
Tested material gastrodine 10mg/kg dosage, gastrodine tablet 50mg/kg effect have some improvement to high fat raising rat hepatic cell fattydegeneration for 4 weeks.
Oil red coloration result: remarkable lipopexia appears in high fat group liver compared with normal matched group, gastrodine 10mg/kg treats and within 4 weeks, can reduce rat liver lipopexia (Fig. 1,2,3).
Blood lipids index:
High fat matched group compared with normal group TC, TG, LDL-c significantly increase.Gastrodine, gastrodine tablet are treated has remarkable effect to These parameters in 2 weeks.In Table 1.
(table 1) gastrodine, gastrodini are on the impact of rat fat (administration 2 weeks)
*, * * is that high fat contrast is compared P < 0.05, P < 0.01 with normal control; #, ## are that administration group and high fat compare P < 0.05, P < 0.01.
Embodiment 3
Rhizoma Gastrodiae micropowder and tablet thereof the therapeutical effect to high lipid food induction rat nonalcoholic fatty liver
1, material
Laboratory animal: 41 of Wistar male rats, body weight 140-160g ，You Institute of Experimental Animals, Chinese Academy of Medical Sciences breeding field provides, and animal (rat) licence is numbered SCXK (capital) 2005-10013; Feeding environment, institute of Materia Medica,Chinese Academy of Medical Sciences experimental animal room (three grades), licence is numbered: SYXK (capital) 2004-0001.
High lipid food fill a prescription 72.5% common normal feedstuff, 10% yolk powder, 10% lard stearin, 5% glucose, 2% cholesterol, 0.5% cholate.Food & Nutrition Department of Institute of Experimental Animals, Chinese Academy of Medical Sciences provides, and feedstuff licence is numbered SCXK-2006-0003.
Medicine: Rhizoma Gastrodiae micropowder, by whole gastrodia tuber, adopt common process to dry, 200 order micronizing make,
The tablet of prescription 4,
Simvastatin (Simvastatin Tablets), Hangzhou Mo Shadong pharmaceutical Co. Ltd produces, lot number: W1093 20060210.
2, method
Rat adaptability starts experiment after raising 5d.Be divided at random 5 groups, be respectively the tablet 560mg/kg group (n=8) of Normal group (n=8), high fat matched group (n=9), simvastatin 10mg/kg group (n=8), Rhizoma Gastrodiae micropowder 1000mg/kg group (n=8), Rhizoma Gastrodiae slice prescription 4.Normal group gives common normal feedstuff; Model control group, Rhizoma Gastrodiae micropowder, prescription 4, simvastatin group give high lipid food.Modeling started drug treatment after 4 weeks, continued to give high lipid food simultaneously.Treat after 8 weeks and put to death animal, get liver and fix with 10% formalin, repair respectively piece, through gradient alcohol dehydration, paraffin embedding, section (thickness 5 μ M), HE dyeing, checks under light microscopic.
3, result
Pathological examination:
1) Normal group: Normal group hepatic tissue has no hepatic cell fattydegeneration, hepatic necrosis, liver proliferation of fibrous tissue and cell infiltration.
2) high fat group: 9 examples (9/9) severe hepatic cell fattydegeneration in high fat group, 5 examples (5/9) cell infiltration, 2 examples (2/9) proliferation of fibrous tissue, 1 example (1/9) lamellar hepatic necrosis.
3) simvastatin group: 5 examples (5/8) severe hepatic cell fattydegeneration in simvastatin group, 3 examples (3/8) moderate hepatic cell fattydegeneration, has no hepatic necrosis, proliferation of fibrous tissue and cell infiltration.
4) Rhizoma Gastrodiae micropowder group: 6 examples (6/8) severe hepatic cell fattydegeneration in Rhizoma Gastrodiae micropowder group, 2 examples (2/8) moderate hepatic cell fattydegeneration, has no hepatic necrosis, proliferation of fibrous tissue and cell infiltration.
5) Rhizoma Gastrodiae slice prescription is 4 groups: 3 examples (3/8) severe hepatic cell fattydegeneration in prescription 4,1 example (1/8) moderate hepatic cell fattydegeneration, has no hepatic necrosis, proliferation of fibrous tissue and cell infiltration.
Conclusion: Rhizoma Gastrodiae micropowder, Rhizoma Gastrodiae slice prescription 4 tablets may have certain preventive effect to animal subject hyperlipidemia model Wistar Liver Damage in Rats in 8 weeks in administration.
In addition, Rhizoma Gastrodiae slice prescription tablet of the present invention to animal subject hyperlipidemia model Wistar, SD Liver Damage in Rats may have certain preventive effect in 4 weeks at administration 8 weeks, gastrodini prescription tablet in administration.
Embodiment 4
The 4 tablet hypolipemic function experiments of Rhizoma Gastrodiae slice prescription
1, materials and methods
Sample prescription 4 tablets.After being pulverized, uses in tablet.
Animal SD male rat, 60, body weight 160～200g, barrier environment.
High lipid food 78.8% normal feedstuff, 1% cholesterol, 10% yolk powder, 10% Adeps Sus domestica, 0.2% bovine bile, wherein normal feedstuff is provided by Henan Province's Experimental Animal Center, clean level, the quality certification number: 0000794.
Reagent and instrument TC, TG, HDL-C test kit provide by Shanghai Ke Hua-Dong Ling diagnostic article company limited.Test instrunment is the ADVIA1200 automatic clinical chemistry analyzer that Bayer is produced.
Dosage is established basic, normal, high three dosage groups, is respectively 5 times, 10 times, 22 times of recommended amounts, and 0.56g/kgBW, 1.12g/kgBW, 2.50g/kg BW, separately establish a hyperlipidemia model matched group and a normal feedstuff matched group.Per os gives tested material, gavage amount 10ml/kg BW.Get respectively given the test agent 5.6g, 11.2g, 25.0g adding distil water to the gavage liquid of 100ml as basic, normal, high dosage group.Hyperlipidemia model matched group and normal feedstuff matched group give solvent distilled water, give continuously 33 days.
Test method normal feedstuff was fed rat after 8 days, spend the night and get tail blood on an empty stomach, survey serum total cholesterol (TC), serum triglycerides (TG), serum High Density Lipoprotein Cholesterol (HDL-C), according to TC level, be divided at random 5 groups, three dosage groups, a hyperlipidemia model matched group and a normal feedstuff matched group.Experimental period,, interior three dosage groups gave the tested material of high lipid food and various dose, and hyperlipidemia model matched group gives high lipid food and distilled water, and normal feedstuff matched group gives normal feedstuff and distilled water.In weighing for the 33rd day of test, fasting was got blood after 16 hours, surveyed serum total cholesterol, triglyceride, three indexs of HDL-C.Result treatment SPSS software carries out variance analysis.
2, result
Impact on animal lipid
Note: normal feedstuff matched group and each dosage group and hyperlipidemia model matched group be * P < 0.05 relatively, * * P < 0.0l.
Note: normal feedstuff matched group and each dosage group and hyperlipidemia model matched group be * * P < 0.01 relatively.
Visible, hyperlipidemia model control animals serum TC, TG and normal feedstuff matched group comparing difference have extremely significantly meaning (P < 0.01), illustrate that this test hyperlipidemia model is successfully established.After test, 2.50g/kgBW dosage group can make TC in rat blood serum reduce, with hyperlipidemia model matched group comparing difference significance (P < 0.05); Test rear three dosage groups and all can make the TG in rat blood serum reduce, have extremely significantly meaning (P < 0.01) with hyperlipidemia model matched group comparing difference; Illustrate that prescription 4 tablets of the present invention have reducing effect to the TC in rat blood serum, TG.
In addition, Rhizoma Gastrodiae slice prescription tablet of the present invention, gastrodini prescription tablet all possess hypolipemic function.
Embodiment 5
The impact of gastrodine on peroxisome fatty acid beta-oxidation key enzyme
1, material
HepG2 cell has this laboratory cultures and goes down to posterity, and 1640 culture medium and hyclone are purchased from Gibco.TriZol test kit is purchased from Invitrogen company, reverse transcription test kit is purchased from Promega company, the quantitative fluorescent PCR Master Mix of premix is purchased from Applied Biosystems company, and PCR primer is as follows: ACOX3 forward primer gcacaactgcccactacga, downstream primer agcttcgaaatcaggggaat; GAPDH forward primer agccacatcgctcagacac, downstream primer gcccaatacgaccaaatcc.ACOX3 monoclonal antibody and β-actin monoclonal antibody are purchased from Santa Cruz Biotechnology.Medicine: gastrodine, white powder, Zhejiang Cheng Yi Pharmaceutical Co., Ltd produces, lot number: 20091005.
Key instrument: iQ5 Multicolor Real-Time PCR Detection System is purchased from Bio-Rad company, and protein electrophoresis groove and electroporation are all purchased from Bio-Rad company.
2, method
HepG2 cell is cultivated in RPMI-1640+10% hyclone, when cell reaches 70%-80% fusion, gastrodine with variable concentrations is processed cell 24 hours, then with TriZol, extract cell total rna, after reverse transcription with the expression of Auele Specific Primer and fluorescence quantitative PCR detection ACOX3mRNA.Take GAPDH as internal reference, utilize ddC
tmethod is calculated relative expression's level (expression of untreated cell ACOX3mRNA is appointed as 1) of ACOX3 mRNA.
Extract again total protein of cell, take β-actin as internal reference, utilize Western blot and specific monoclonal antibody to measure the protein expression level of ACOX3.
Statistical analysis: variance analysis is in conjunction with t check between group.
3, result
ACOX3 is peroxisome fatty acid beta-oxidation key enzyme, and its defect can cause disorders of lipid metabolism, liver fat to be accumulated.It is expressed to increase and contributes to improve lipid metabolism.
As shown in Figure 4, the mrna expression level of energy dose dependent rise ACOX3 after gastrodine processing HepG2 cell.As shown in Figure 5, the protein expression level of energy dose dependent rise ACOX3 after gastrodine processing HepG2 cell.
In sum, experiment showed, that gastrodine/Rhizoma Gastrodiae has the clear and definite effect that alleviates non-alcoholic fatty liver disease, and its mechanism of action is unique, there are no relevant report.Can be used as the new purposes of exploitation this Chinese medicine of Rhizoma Gastrodiae and gastrodine monomer.
The new effect for the treatment of non-alcoholic fatty liver disease and the molecule mechanism of gastrodine/Rhizoma Gastrodiae of the present invention, be also applicable to any derivant of gastrodine structure and the Rhizoma Gastrodiae powder of any granularity.
Embodiment 6
The report of auxiliary lipid-lowering function human feeding trial
1, materials and methods
Be subject to trial product: the tablet product of Rhizoma Gastrodiae slice prescription 4.
Study subject:
Inclusive criteria, the crowd of simple dyslipidemia, keeps usual diet, in half a year, blood sampling is 2 times, as 2 serum total cholesterols all >=5.2mmol/L or triglyceride >=1.65mmol/L.To meet above-mentioned condition and voluntary participation and guarantee that cooperation person, as alternative objects, includes test in.During tested, keep usual life and dietary habit.
Exclusion standard: the age under-18s or over-65s person, gestation or women breast-feeding their children, to health food allergy sufferers; Merge intentionally, the serious disease such as liver, kidney and hemopoietic system, psychotic, take in a short time the article relevant with tested function, have influence on the judgement person to result, do not meet inclusive criteria, do not eat in accordance with regulations given the test agent, cannot judge effect or data not umbra sound effect or safety judgement person.
2, grouping and test-meal method
Adopt 2 kinds of control design between self and group.104 experimenters are divided into test-meal group and matched group (each 52 examples of test-meal group and matched group) at random by serum levels.On affecting the principal element of result, as carrying out harmony, sex, age, diet etc. check, to guarantee comparability between group.Test-meal group is taken tested material, and matched group is blank.Taking dose and time: each 3, every day 3 times, taking dose is 6.75 grams/day.Continuous 45 days, keep usual life and dietary habit during tested.
Reagent and instrument
Italy Autolab type automatic clinical chemistry analyzer, Japanese CA-500 type blood counting instrument, U.S. BM-200 urinates ten analysers, U.S. TH600 star X scenograph, U.S. MAC5000 type electrocardiograph, Syneogy type B ultrasonic diagnostic apparatus.The whole You Zhongsheng of biochemical reagents box company provides.
Observation index: indices starts front and finishes rear each and detect once in test-meal.
Safety indexes detects
Ordinary circumstance: comprise spirit, sleep, diet, defecation, blood pressure etc.
Blood, urine, stool routine examination inspection.
Hepatic and renal function checks: total serum protein, albumin, glutamate pyruvate transaminase, glutamic oxaloacetic transaminase, GOT, creatinine, blood urea nitrogen, blood glucose.
Other index; Electrocardiogram, Chest X-rays, Abdominal B type ultrasonography (only checking before on-test).
Efficiency index
Serum total cholesterol (TC) level and reduction percentage rate, triglyceride (TG) level and reduction percentage rate, HDL-C (HDL-C) level and ascensional range.
Efficiency index criterion:
Effective: TC reduces > 10%, TG reduces > 15%, HDL-C rising > 0.104mmol/L.
Invalid: not reach efficiency index person.
Observe TC effective percentage, TG effective percentage, HDL-C effective percentage and total effective rate.
Date processing and and result judge:
All own control data can adopt paired t-test, and two groups of means relatively adopt t check in groups, and the latter need carry out homogeneity test of variance, the data of nonnormal distribution heterogeneity of variance are carried out to suitable variable conversion, after meeting normal state variance.By the data of conversion, carry out t check, effective percentage adopts x
2check is tested.
Serum total cholesterol after comparison test-meal, triglyceride, HDL-C situation of change, between test-meal group self comparison and test-meal group and matched group group, comparing difference has significance, and reaches effective standard, can judge TC, TG, the HDL-C result positive.T-CHOL, two index positives of triglyceride, HDL-C, not significantly lower than matched group, can judge that given the test agent has auxiliary lipid-lowering function.
3, result
Qualified experimenter 100 people, are divided into blank group and test-meal group at random, test-meal group and matched group 50 example; The product of taking prescription 4 according to crowd's test-meal recommendation consumption is after 45 days, cholesterol 0.65 ± the 0.73mmol/L that on average declines, decline percentage rate 10.35%, between test-meal group self comparison and test-meal group and matched group group, comparing difference has significance (P < 0.01).Triglyceride 0.38 ± the 0.49mmol/L that on average declines, decline percentage rate 15.78%, between test-meal group self comparison and test-meal group and matched group group, comparing difference has significance (P < 0.05, P < 0.01); The test-meal group HDL-C 0.11 ± 0.15mmol/L that on average raises.In 50 routine test-meal groups, there are 14 examples effectively, total effective rate 28.00%.Chest X-rays before test-meal.Abdominal B type ultrasonography, Electrocardioscopy show no obvious abnormalities, and before and after the safety indexes test-meals such as two groups of hemogram, renal function, without significant change, routine urinalysis and stool detect Non Apparent Abnormality before and after index test-meal, have no irritated and other untoward reaction before and after test-meal.Illustrate that this product has no adverse effects to experimenter's health.
Claims (10)
1. Rhizoma Gastrodiae is treated the purposes in non-alcoholic fatty liver disease medicine, food, health product in preparation.
2. purposes according to claim 1, is characterized in that, the purposes of the gastrodine in Rhizoma Gastrodiae in preparation treatment non-alcoholic fatty liver disease medicine, food, health product.
3. purposes according to claim 1, is characterized in that, the gastrodine in Rhizoma Gastrodiae is being prepared the purposes of the medicine of rise hepatocyte ACOD 3 mRNA of (ACOX3) and the expression of albumen, food, health product.
4. purposes according to claim 1 and 2, is characterized in that, Rhizoma Gastrodiae or gastrodine are made peroral dosage form.
5. purposes according to claim 1, Rhizoma Gastrodiae adopts micropowder, and its granularity is 200-1000 order.
6. purposes according to claim 1, Rhizoma Gastrodiae adopts rice fiber crops, the numb composition of arrow of following ratio: the ratio between rice fiber crops and arrow fiber crops is: 1-10: 20-300; Wherein the granularity of rice fiber crops is that the granularity of 200-1000 order, arrow fiber crops is 80-600 order.
7. purposes according to claim 1, the dosage of Rhizoma Gastrodiae is 200-1000 milligram.
8. purposes according to claim 2, the dosage of gastrodine is 5-10 milligram.
9. according to the dosage form of the purposes described in claim 7 or 8: it is characterized in that: tablet, this tablet composed as follows:
800 20-40 gram of order rice fiber crops, 200 order arrow fiber crops 220-500 gram; Or gastrodine 3-10 gram
200 order recrystallization lactose 40-120 gram, and, 600 order spray-dried lactose 50-140 gram; With
Pregelatinized Starch 10-40 gram; With
Magnesium stearate 2-10 gram; With
Sodium ascorbate 2-6 gram.
10. according to the dosage form of the purposes described in claim 7 or 8: it is characterized in that: tablet, this tablet composed as follows:
800 20-40 gram of order rice fiber crops, 200 order arrow fiber crops 220-500 gram; Or gastrodine 3-10 gram
200 order recrystallization lactose 40-120 gram, and, 600 order spray-dried lactose 50-140 gram; With
Microcrystalline Cellulose 20-40 gram;
Pregelatinized Starch 10-40 gram; With
Crospolyvinylpyrrolidone 40-80 gram; With
Magnesium stearate 2-10 gram; With
Micropowder silica gel 2-10 gram.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210276077.2A CN103566198B (en) | 2012-08-06 | 2012-08-06 | Rhizoma Gastrodiae and gastrodine treat the application of the product of non-alcoholic fatty liver disease in preparation |
| CN201510790050.9A CN105560908A (en) | 2012-08-06 | 2012-08-06 | Application of Rhizoma Gastrodiae and gastrodin in treating non-alcoholic fatty liver |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210276077.2A CN103566198B (en) | 2012-08-06 | 2012-08-06 | Rhizoma Gastrodiae and gastrodine treat the application of the product of non-alcoholic fatty liver disease in preparation |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510790050.9A Division CN105560908A (en) | 2012-08-06 | 2012-08-06 | Application of Rhizoma Gastrodiae and gastrodin in treating non-alcoholic fatty liver |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103566198A true CN103566198A (en) | 2014-02-12 |
| CN103566198B CN103566198B (en) | 2016-04-20 |
Family
ID=50039479
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510790050.9A Pending CN105560908A (en) | 2012-08-06 | 2012-08-06 | Application of Rhizoma Gastrodiae and gastrodin in treating non-alcoholic fatty liver |
| CN201210276077.2A Active CN103566198B (en) | 2012-08-06 | 2012-08-06 | Rhizoma Gastrodiae and gastrodine treat the application of the product of non-alcoholic fatty liver disease in preparation |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510790050.9A Pending CN105560908A (en) | 2012-08-06 | 2012-08-06 | Application of Rhizoma Gastrodiae and gastrodin in treating non-alcoholic fatty liver |
Country Status (1)
| Country | Link |
|---|---|
| CN (2) | CN105560908A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104491496A (en) * | 2015-01-14 | 2015-04-08 | 中国医学科学院医药生物技术研究所 | Application of gastrodin/gastrodia powder in anti-liver fibrosis medicine preparation |
| CN106176780A (en) * | 2016-08-31 | 2016-12-07 | 昆药集团股份有限公司 | A kind of new opplication of gastrodine |
| CN106619667A (en) * | 2016-11-19 | 2017-05-10 | 昆药集团股份有限公司 | Application of acegastrodine and acegastrodine derivative |
| CN107929293A (en) * | 2017-11-16 | 2018-04-20 | 中国医学科学院医药生物技术研究所 | Application of the Gastrodin in preventing or treating alcoholic liver medicine |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114073682A (en) * | 2021-09-17 | 2022-02-22 | 曲阜师范大学 | Microcapsule decoction piece embedded with components for preventing and improving non-alcoholic fatty liver and preparation method thereof |
| CN115161149A (en) * | 2022-07-21 | 2022-10-11 | 贵州九龙天麻有限公司 | Gastrodia elata compound wine and preparation process and application thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101439154A (en) * | 2008-08-21 | 2009-05-27 | 北京协医振兴科技开发中心 | Gastrodia tuber medicament for treating insomnia |
| CN101524481A (en) * | 2009-04-17 | 2009-09-09 | 暨南大学 | Chinese herbal compound for preventing and curing fatty liver |
| CN101524386A (en) * | 2009-04-17 | 2009-09-09 | 暨南大学 | Chinese herbal main component prescription for curing fatty liver |
-
2012
- 2012-08-06 CN CN201510790050.9A patent/CN105560908A/en active Pending
- 2012-08-06 CN CN201210276077.2A patent/CN103566198B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101439154A (en) * | 2008-08-21 | 2009-05-27 | 北京协医振兴科技开发中心 | Gastrodia tuber medicament for treating insomnia |
| CN101524481A (en) * | 2009-04-17 | 2009-09-09 | 暨南大学 | Chinese herbal compound for preventing and curing fatty liver |
| CN101524386A (en) * | 2009-04-17 | 2009-09-09 | 暨南大学 | Chinese herbal main component prescription for curing fatty liver |
Non-Patent Citations (2)
| Title |
|---|
| 于滨等: "天麻细粉和天麻素降血脂作用的实验研究", 《中国医药生物技术》 * |
| 李福辉等: "非酒精性脂肪肝的临床特点及与血脂血糖的关系", 《中国误诊学杂志》 * |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104491496A (en) * | 2015-01-14 | 2015-04-08 | 中国医学科学院医药生物技术研究所 | Application of gastrodin/gastrodia powder in anti-liver fibrosis medicine preparation |
| CN104491496B (en) * | 2015-01-14 | 2017-08-18 | 中国医学科学院医药生物技术研究所 | Application of the Gastrodin/Rhizoma Gastrodiae powder in anti-hepatic fibrosis medicines are prepared |
| CN106176780A (en) * | 2016-08-31 | 2016-12-07 | 昆药集团股份有限公司 | A kind of new opplication of gastrodine |
| CN106619667A (en) * | 2016-11-19 | 2017-05-10 | 昆药集团股份有限公司 | Application of acegastrodine and acegastrodine derivative |
| CN107929293A (en) * | 2017-11-16 | 2018-04-20 | 中国医学科学院医药生物技术研究所 | Application of the Gastrodin in preventing or treating alcoholic liver medicine |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103566198B (en) | 2016-04-20 |
| CN105560908A (en) | 2016-05-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103566198B (en) | Rhizoma Gastrodiae and gastrodine treat the application of the product of non-alcoholic fatty liver disease in preparation | |
| Zheng et al. | Maternal resveratrol consumption and its programming effects on metabolic health in offspring mechanisms and potential implications | |
| CN1457808A (en) | Iron scale dendrobium compound preposition and preparation and use | |
| CN101836725A (en) | Application of red rice residue product in preparing health-care food for lowering blood fat | |
| CN103830577A (en) | Medicine composition for treating liver and gall calculus and kidney stone and application thereof | |
| Chitsaz et al. | EFFECT OF CHLORELLA VULGARIS VS. SPIRULINA SUPPLEMENTATION ON LIPID PROFILE AND LIVER FUNCTION IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE: A RANDOMIZED CONTROLLED TRIAL. | |
| CN106063795B (en) | The application of forsythin, its derivative, forsythin and phillygenol composition in preparation prevention or/and treatment hyperlipemia drug | |
| WO2015190872A1 (en) | Pharmaceutical composition containing spirulina maxima extract as active ingredient for treating and preventing obesity | |
| CN102430078A (en) | Medicine for treating acute gouty arthritis and preparation method thereof | |
| CN100393321C (en) | Oral antilipemic liquid and its preparing method | |
| CN106581007A (en) | Application of ilexgenin A in preparation of anti-atherosclerosis drugs | |
| CN103690573A (en) | Natural pharmaceutical composition for enhancing immunity and preparation method of natural pharmaceutical composition | |
| CN108926595A (en) | A kind of health care product with protection liver and hypolipemic function | |
| WO2022237731A1 (en) | Pharmaceutical composition for treating hyperlipidemia and preparation method therefor | |
| CN104083368A (en) | Application of G-1 in preparation of G protein coupled receptor 30-based triple negative breast cancer targeting drugs | |
| CN101879190A (en) | Composition containing curcumin and application of curcumin in preparing composition for adjusting blood sugar | |
| CN105534966A (en) | Application of gamma-aminobutyric acid as active ingredient for enhancing chemotherapeutic sensitivity | |
| CN103006627B (en) | Application of resveratrol in preparation of composition for preventing and/or treating systemic lupus erythematosus | |
| Mao et al. | Exploring the mechanism of Pueraria lobata (Willd.) Ohwi in the regulation of obesity | |
| US20180177836A1 (en) | Traditional chinese medicine composition for promotion of browning of white adipocytes, preparation method and use thereof | |
| CN109718342A (en) | It is a kind of for treating or assisting in the treatment of the Chinese medicine composition, preparation, preparation method and its usage of chronic kidney disease | |
| CN100389799C (en) | Tibetan medicine for relieving pain and its preparing method | |
| Qodria et al. | Anti‐proliferative effects of pentagamaboronon‐0‐sorbitol on HER2‐overexpressing breast cancer cells | |
| CN103585583A (en) | Traditional Chinese medicine composition for treating hepatic calculus and application thereof | |
| CN106728155A (en) | Reducing blood lipid, the anaesthetic composition of antiatherosclerosis and preparation method and application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |